Dikkat eksikliği hiperaktivite bozukluğu olan bir ergende modifiye salımlı metilfenidat kaynaklı Raynaud fenomeni

Year 2022, Volume: 47 Issue: 3, 1381 - 1383, 30.09.2022

Nur Seda Gülcü Üstün , Ali Karayağmurlu

https://doi.org/10.17826/cumj.1121992

Abstract

Dikkat eksikliği/hiperaktivite bozukluğu (DEHB), 12 yaşından önce başlayan ve gelişimsel olarak uygun olmayan dikkatsizlik, hiperaktivite ve/veya dürtüsellik belirtileri ile karakterize nörogelişimsel bir bozukluktur. Metilfenidat (MPH) gibi uyarıcılar, DEHB olan çocuklar için birinci basamak tedavi olarak kullanılmaktadır. Psikostimulanlar vasküler problemlerle ilişkili olabilir. Raynaud fenomeni (RF), soğuk ve duygusal stres tarafından tetiklenen tekrarlayan geri dönüşümlü vazospazm atakları ile karakterize bağ dokusu hastalıkları ile potansiyel olarak ilişkili bir periferik vaskülopatidir. MPH ile gözlenen RF'yi içeren birkaç vaka yayınlanmıştır. Bu rapor, 27 mg ozmotik salınım (OROS)-MPH tedavisi sırasında 10 mg modifiye salınımlı MPH eklenmesiyle RP yaşayan, ancak 36 mg OROS-MPH tedavisi sırasında görülmeyen DEHB'li 14 yaşında bir kız çocuğunu tartışmaktadır.

Keywords

DEHB, metilfenidat, Raynaud fenomeni

Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder commencing before the age of 12 years and characterized by developmentally inappropriate inattention, hyperactivity, and/or impulsivity symptoms. Stimulants such as methylphenidate (MPH) are used as first-line therapy for children with ADHD. Psychostimulants may be associated with vascular problems. Raynaud’s phenomenon (RP) is a peripheral vasculopathy potentially associated with connective tissue diseases characterized by recurring reversible vasospasm attacks triggered by cold and emotional stress. Several cases have been published involving RP observed with MPH. The present report discusses a 14-year-old girl with ADHD who experienced RP with the addition of 10 mg modified-release MPH during 27 mg osmotic release (OROS)-MPH therapy, but not during 36 mg OROS-MPH therapy.

Keywords

ADHD, methylphenidate, raynaud phenomena

References

• REFERENCES 1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
• 2. Ercan ES, Polanczyk G, Akyol Ardıc U, Yuce D, Karacetın G, Tufan AE, Tekden M. (2019). The prevalence of childhood psychopathology in Turkey: a cross-sectional multicenter nationwide study (EPICPAT-T). Nordic journal of psychiatry, 73(2), 132-140.
• 3. Golmirzaei J, Mahboobi H, Yazdanparast M, Mushtaq G, A Kamal M, Hamzei E. (2016). Psychopharmacology of attention-deficit hyperactivity disorder: effects and side effects. Current pharmaceutical design, 22(5), 590-594.
• 4. de Sousa ADF, Coimbra IM, Castanho JM, Polanczyk GV, Rohde LA. (2020). EXTERNALIZING DISORDERS.Chapter D.1:1-28.
• 5. Cantu C, Arauz A, Murillo Bonilla LM, López M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34(7):1667–72.
• 6. Jefferson HJ, Jayne DR Peripheral vasculopathy and nephropathy in association with phentermine. Nephrol Dial Transplant. 1999;14(7):1761–3.
• 7. Kokkinos J, Levine SR. Possible association of ischemic stroke with phenteramine. Stroke. 1993;24:310 –313.
• 8. Karayagmurlu A, Coskun M. (2020). Successful management of methylphenidate or atomoxetine-related priapism during attention-deficit hyperactivity disorder treatment. Journal of Clinical Psychopharmacology, 40(3), 314-315.
• 9. Prete M, Fatone MC, Favoino E, Perosa F. Raynaud’s phenomenon: From molecular pathogenesis to therapy. Autoimmun Rev [Internet]. 2014;13(6):655–67.
• 10. Jones GT, Herrick AL, Woodham SE et al. Occurrence of Raynaud’s phenomenon in children ages 12– 15 years: prevalence and association with other common symptoms. Arthritis Rheum 2003;48:3518–3521.)
• 11. Herrick AL: Pathogenesis of Raynaud’s phenomenon. Rheumatology (Oxford) 44:587–596, 2005.
• 12. Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J Clin Rheumatol. 2008;14(1):30–3.
• 13. Yu ZJ, Parker-Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2010;12(2):111–5.
• 14. Ferahkaya H, Akça ÖF. Methylphenidate-Induced Raynaud’s Phenomenon In Two Cases With Attention-Deficit/Hyperactivity Disorder. Journal of Contemporary Medicine, 11(3 (Forthcoming Issue-Gelecek Sayı)), 1-2.
• 15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245, 1981.
• 16. Goldman W, Seltzer R, Reuman P: Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children. Arthritis Rheum 58:563–566, 2008.
• 17. Bayram Ö, Hergüner S. OROS-methylphenidate-induced Raynaud’s phenomenon: A dose-related side effect. J Child Adolesc Psychopharmacol. 2015;25(6):521–2.
• 18. Meridor K, Levy Y. (2020). Systemic sclerosis induced by CNS stimulants for ADHD: a case series and review of the literature. Autoimmunity reviews, 19(1), 102439.
• 19. Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol 2016;82:6–16. https://doi.org/10.1111/bcp.12912.
• 20. Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–70.
• 21. Monteerarat Y, Pariwatcharakul P. (2019). Methylphenidate-Induced Raynaud Phenomenon Developed After Increasing Methylphenidate in an Adult With Attention-Deficit Hyperactivity Disorder. Journal of clinical psychopharmacology, 39(2), 178-179.)